Histone Deacetylase 10-inhibitor Co-Treatment in Cancer
Histone deacetylase inhibitors (HDACi) are promising anticancer agents and are currently being evaluated in clinical trials. However, due to their unselective action, pan-HDACi exhibit dose-limiting side-effects restricting their full potential in anti-cancer therapy. Therefore, characterization of the molecular function of single HDAC isozymes is of major importance for a targeted therapy with less side-effects. We show that HDAC10 overexpression mediated cell survival and targeting of HDAC10 sensitized tumor cells for cytotoxic drug treatment and it correlates with progression or recurrence of neuroblastoma in vivo. These results demonstrate for the first time that HDAC10 induces an alternative lysosomal-mediated tumor cell death pathway, re-sensitizes cells for cytotoxic drugs and may thus be a novel strategy for neuroblastoma therapy.
Further Information: PDF
Deutsches Krebsforschungszentrum DKFZ
Phone: +49-6221-42 2955
Contact
Dr. Ruth Herzog
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Why getting in touch with our ‘gerbil brain’ could help machines listen better
Macquarie University researchers have debunked a 75-year-old theory about how humans determine where sounds are coming from, and it could unlock the secret to creating a next generation of more…
Attosecond core-level spectroscopy reveals real-time molecular dynamics
Chemical reactions are complex mechanisms. Many different dynamical processes are involved, affecting both the electrons and the nucleus of the present atoms. Very often the strongly coupled electron and nuclear…
Free-forming organelles help plants adapt to climate change
Scientists uncover how plants “see” shades of light, temperature. Plants’ ability to sense light and temperature, and their ability to adapt to climate change, hinges on free-forming structures in their…
